Robert M. Davis
Chief executive: Merck & Co., Inc. (1 Jul 2021 to present)
6commitments announced
5with a clear outcome
5met on time
–rate shown after 15 outcomes
Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Merck & Co., Inc. filing.
Commitments announced under Robert M. Davis
| Merck & Co., Inc.announced 24 Apr 2025 | Close the exclusive license agreement with Hengrui Pharma for an oral Lp(a) inhibitor | Met30 Jun 2025 |
| Merck & Co., Inc.announced 27 Apr 2023 | Close the acquisition of Prometheus Biosciences | Met30 Sep 2023 |
| Merck & Co., Inc.announced 27 Apr 2023 | Start Phase 3 studies for MK-0616 | No record found31 Dec 2023 |
| Merck & Co., Inc.announced 28 Apr 2022 | Advance V116 pneumococcal conjugate vaccine to Phase 3 clinical trials | Met31 Dec 2022 |
| Merck & Co., Inc.announced 28 Oct 2021 | Close the acquisition of Acceleron Pharma | Met31 Dec 2021 |
| Merck & Co., Inc.announced 29 Jul 2021 | Initiate the withdrawal of the accelerated approval indication for KEYTRUDA for gastric cancer | Met31 Jan 2022 |
Is this record wrong, or are you Robert M. Davis? Add a statement or ask for a correction.